Treatment Diabetic Macular Edema

Sponsor: Genetech – Thames

In this study, we are recruiting patients with moderate stages of diabetic retinopathy. The primary cause of vision loss in diabetic retinopathy is the development of diabetic macular edema or DME. DME occurs due to leaky blood vessels in the center part of the retina which causes thickening of the retina and vision loss. The mainstay of therapy in diabetic macular edema has been a combination of laser, anti-VEGF, and steroid therapy. This study utilizes a novel molecule that activates the Tie2 pathway which has been shown to promote vascular stability and prevent vascular leakage. In this study, patients will either receive the study medication in combination with Eylea or Vabysmo, or Eylea or Vabysmo alone. The study will be conducted over a 1 year period At any point in the study, if a patient is not responding well to therapy and meets rescue criteria, they will be treated with standard of care treatment. We hope this trial will be able to demonstrate that direct Tie2 activation in combination with currently utilized anti-VEGF therapies will show improved efficacy compared to anti-VEGF therapy alone.

For more information, visit gene.com or connect with one of our clinical coordinators.